Targeted Oncology46m
FDA Grants Perioperative Pembrolizumab Priority Review in HNSCC
The FDA granted priority review to pembrolizumab for neoadjuvant and adjuvant use in head and neck squamous cell carcinoma, ...
Cure Today1h
FDA Accepts Priority Review for Pre- and Postsurgical Keytruda in HNSCC
The FDA accepted for priority review a supplemental Biologics License Application for Keytruda for resectable locally ...
Pharm Exec3h
FDA Grants Priority Review to Merck’s Keytruda for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Keytruda demonstrated a statistically significant and clinically meaningful improvement in event-free survival and major ...
The Pharma Letter5h
FDA grants priority review to Merck’s sBLA for Keytruda
The US Food and Drug Administration (FDA) has accepted for priority review a new supplemental Biologics License Application ...
Le Lézard9h
National survey reveals low understanding of shingles risk factors and lack of concern among those at increased risk
Among those with a chronic condition, concern of getting shingles is low with only 12% highly concerned and 37% somewhat concerned Over 80% of those with a chronic condition have not been informed by ...
Merck’s application for keytruda in HNSCC granted priority review by FDA
Merck (MRK) announced the FDA has accepted for priority review a new supplemental Biologics License Application seeking approval for keytruda – ...
FDA accepts BMS’ Opdivo-Yervoy combo sBLA for colorectal cancer
The US Food and Drug Administration (FDA) has accepted Bristol Myers Squibb’s (BMS) supplemental biologics licence ...